Global Autism Disorder Treatment Market Opportunities and Forecast 2020-2027
- DLR2107
- 20 September, 2020
- Pharma & Healthcare
- Pages: 120
- Global
Global Autism Disorder Treatment Market, By Type (Bare Metal, Drug Eluting, BVS), By Offering (Hardware, Software) By End User (Hospital, ASC, Cardiology Center) opportunities and forecast 2020-2027
Market Overview
Autism disorders are range of neurobehavioral disorders which affect the ability of patients to connect with others. The infections may also manifest in form of lack of social skills, difficulty in accepting nonverbal message, speech, and other symptoms. The development of autism is not understood well, but symptoms can be observe most strongly around age of two to three years.
Rising awareness about disorders is expected to be major driver for global autism disorder treatment market during the forecast period, as overall awareness about prevalence of disorders and their treatment is deficient, especially in developing economies. Rising efforts into research are expected to remain key driver for global autism disorder treatment market during the forecast period. Growing efforts by the parents to seek individually oriented treatments for the diseased children are likely to be major driver for global autism disorder treatment market.
Segment Overview
Fusion Autism Center or (FAC), mental health service provider, in the U.S., announced that it has successfully extended its center-based services of the Applied Behavioral Analysis (ABA) therapy for kids on autism spectrum In Feb 2019. The new centre is built in August so that it would deliver much-needed services to communities with the special needs residing in that area. Apart from this, FAC has its centers in Woodstock, Roswell, Cumming, Duluth, and Peachtree.
Regional Overview
The North America segment holds dominant share in global autism disorder treatment market owing to growing prevalence of the disease in the region and high awareness among the parents about disease. The growing availability of advanced disorder medication and the treatment in Canada and the U.S. is expected to be major driver for autism disorder treatment market in North America over the projection period.
Q BioMed Inc., prominent developer of the biomedical assets, in June 2018, declared that it has applied for the Orphan Drug status with the U.S. and European regulators for QBM-001, company’s pediatric autism drug.
Competitive Overview
Some of the major players in the global autism disorders treatment market are Allergan, Q BioMed Inc., Fusion Autism Center, Hopebridge, LLC., Pfizer Inc,. and various others.
Key Players
Market Segmentation
By Type
Market Overview
Autism disorders are range of neurobehavioral disorders which affect the ability of patients to connect with others. The infections may also manifest in form of lack of social skills, difficulty in accepting nonverbal message, speech, and other symptoms. The development of autism is not understood well, but symptoms can be observe most strongly around age of two to three years.
Rising awareness about disorders is expected to be major driver for global autism disorder treatment market during the forecast period, as overall awareness about prevalence of disorders and their treatment is deficient, especially in developing economies. Rising efforts into research are expected to remain key driver for global autism disorder treatment market during the forecast period. Growing efforts by the parents to seek individually oriented treatments for the diseased children are likely to be major driver for global autism disorder treatment market.
Segment Overview
Fusion Autism Center or (FAC), mental health service provider, in the U.S., announced that it has successfully extended its center-based services of the Applied Behavioral Analysis (ABA) therapy for kids on autism spectrum In Feb 2019. The new centre is built in August so that it would deliver much-needed services to communities with the special needs residing in that area. Apart from this, FAC has its centers in Woodstock, Roswell, Cumming, Duluth, and Peachtree.
Regional Overview
The North America segment holds dominant share in global autism disorder treatment market owing to growing prevalence of the disease in the region and high awareness among the parents about disease. The growing availability of advanced disorder medication and the treatment in Canada and the U.S. is expected to be major driver for autism disorder treatment market in North America over the projection period.
Q BioMed Inc., prominent developer of the biomedical assets, in June 2018, declared that it has applied for the Orphan Drug status with the U.S. and European regulators for QBM-001, company’s pediatric autism drug.
Competitive Overview
Some of the major players in the global autism disorders treatment market are Allergan, Q BioMed Inc., Fusion Autism Center, Hopebridge, LLC., Pfizer Inc,. and various others.
Key Players
- Allergan
- Center for Autism and Related Disorders.
- Q BioMed Inc
- Hopebridge, LLC.
- Behavior Innovations
- Fusion Autism Center
- Applied Behavior Consultants
- Otsuka Holdings Co. Ltd.
- Pfizer Inc.
- Eli Lilly and Company
- AstraZeneca
- Johnson & Johnson Services, Inc.
Market Segmentation
By Type
- Autistic Disorder
- Pervasive Developmental Disorder
- Asperger Syndrome
- Others
- Drug Therapies
- Communication & Behavioral Therapies
- North America
- US
- Canada
- Europe
- UK
- Germany
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- UAE
- Rest of LAMEA
1 Report Prologue 12
2 Market Introduction 16
- 2.1 Scope of Study 17
- 2.2 Research Objective 17
- 2.3 Assumptions & Limitations 17
- 2.3.1 Assumptions 17
- 2.3.2 Limitations 17
3 Research Methodology 18
- 3.1 Primary Research Methodology 19
- 3.2 Secondary Research Methodology 20
- 3.3 Market Share Analysis 21
- 3.4 Trade Analysis 21
- 3.5 Market Pricing Approach 21
4 Market Dynamics 22
- 4.1 Introduction 23
- 4.2 Drivers 24
- 4.2.1 Rising Prevalence of Autism Disorder and Pervasive Developmental Disorder Have Fueled the Growth of the Market.(PDD) 24
- 4.2.2 Expected Approvals of Off-Label Drugs to Treat Autism Disorder Has Driven the Market Growth 25
- 4.2.3 Rising government or privately held societies taking initiatives to create the awareness about the disease 26
- 4.3 Restraints 27
- 4.3.1 Weak Product Pipeline of First Drugs for Autism 27
- 4.3.2 Unknown Etiology and Pathophysiology of the Disorder Prevent Effective Treatment Options 28
- 4.4 Opportunities 29
- 4.4.1 Rising Investments by Venture Non-Pharmacology Activities 29
- 4.5 Mega Trends: 30
- 4.6 Macroeconomic Indicators 30
5 Market Factor Analysis 31
- 5.1 Porter’s Five Forces Model 32
- 5.1.1 Bargaining Power of Suppliers 33
- 5.1.2 Bargaining Power of Buyers 33
- 5.1.3 Threat of New Entrants 33
- 5.1.4 Threat of Substitutes 33
- 5.1.5 Intensity of Rivalry 33
- 5.2 Value Chain Analysis 34
- 5.2.1 R&D 34
- 5.2.2 Manufacturing 34
- 5.2.3 Distribution & Sales 34
- 5.2.4 Post-Sales Monitoring 35
- 5.3 Pricing Analysis 36
- 5.4 Investment Opportunity Analysis 36
- 5.5 Demand & Supply: Gap Analysis 36
6 Global Autism Disorder & Treatment Market, By Type 38
- 6.1 Introduction 39
- 6.2 Asperger Syndrome 40
- 6.3 Pervasive Developmental Disorders (PDDs) 40
7 Global Autism Disorder & Treatment Market, By Treatment Type 41
- 7.1 Introduction 42
- 7.2 Expert Opinion: Oxytocin 42
- 7.3 ABA (applied behavioral analysis) 43
- 7.4 Hyperbaric oxygen therapy 44
- 7.5 Chelation therapy 44
- 7.6 Oxytocin therapy 44
8 Global Autism Disorder & Treatment Market, By Drugs 45
- 8.1 Introduction 46
- 8.2 Selective Serotonin Reuptake Inhibitors (SSRIs) 47
- 8.3 Anti-convulsants 48
- 8.4 Stimulants 48
- 8.5 Anti-psychotic 48
9 Global Autism Disorder & Treatment Market, By Region 49
- 9.1 Introduction 50
- 9.2 Americas 51
- 9.3 North America 54
- 9.3.1 U.S. 54
- 9.4 Canada 55
- 9.4.1 South America 56
- 9.5 Europe 57
- 9.5.1 Germany 60
- 9.5.2 France 61
- 9.5.3 UK 62
- 9.5.4 Italy 63
- 9.5.5 Spain 64
- 9.5.6 Rest of Western Europe 65
- 9.5.7 Eastern Europe 66
- 9.6 Asia Pacific 67
- 9.6.1 Japan 69
- 9.6.2 China 70
- 9.6.3 India 71
- 9.6.4 Australia 72
- 9.6.5 Republic of Korea 73
- 9.6.6 Rest of Asia Pacific 74
- 9.7 Middle East & Africa 76
- 9.7.1 UAE 78
- 9.7.2 Saudi Arabia 79
- 9.7.3 Oman 80
- 9.7.4 Kuwait 81
- 9.7.5 Qatar 82
- 9.7.6 Rest of Middle East & Africa 83
10 Competitive Landscape 85
- 10.1 Company Market Share Analysis 86
- 10.1.1 Introduction 86
- 10.2 Competitive Landscape 87
- 10.2.1 Introduction 87
- 10.3 Recent Developments, 2013-2018 88
11 Company Profiles 90
- 11.1 Pfizer Inc. 91
- 11.1.1 Company Overview 91
- 11.1.2 Financials 91
- 11.1.3 Products 91
- 11.1.4 Strategy 91
- 11.1.5 Key Developments 91
- 11.2 Allergan, Plc 92
- 11.2.1 Company Overview 92
- 11.2.2 Financials 92
- 11.2.3 Products 92
- 11.2.4 Strategy 92
- 11.2.5 Key Developments 92
- 11.3 Eli Lilly and Company 93
- 11.3.1 Company Overview 93
- 11.3.2 Financials 93
- 11.3.3 Products 93
- 11.3.4 Strategy 93
- 11.3.5 Key Developments 93
- 11.4 Bristol-Myers Squibb Company 94
- 11.4.1 Company Overview 94
- 11.4.2 Financials 94
- 11.4.3 Products 94
- 11.4.4 Strategy 94
- 11.4.5 Key Developments 94
- 11.5 Sun Pharmaceutical Industries Ltd. 95
- 11.5.1 Company Overview 95
- 11.5.2 Financials 95
- 11.5.3 Products 95
- 11.5.4 Strategy 95
- 11.5.5 Key Developments 95
- 11.6 Johnson & Johnson Services, Inc. 96
- 11.6.1 Company Overview 96
- 11.6.2 Financials 96
- 11.6.3 Products 96
- 11.6.4 Strategy 96
- 11.6.5 Key Developments 96
- 11.7 Teva Pharmaceutical Industries Ltd. 97
- 11.7.1 Company Overview 97
- 11.7.2 Financials 97
- 11.7.3 Products 97
- 11.7.4 Strategy 97
- 11.7.5 Key Developments 97
- 11.8 Merck & Co. Inc 98
- 11.8.1 Company Overview 98
- 11.8.2 Financials 98
- 11.8.3 Products 98
- 11.8.4 Strategy 98
- 11.8.5 Key Developments 98
- 11.9 Novartis AG 99
- 11.9.1 Company Overview 99
- 11.9.2 Financials 99
- 11.9.3 Products 99
- 11.9.4 Strategy 99
- 11.9.5 Key Developments 99
- 11.10 Otsuka Holdings Co. Ltd 100
- 11.10.1 Company Overview 100
- 11.10.2 Financials 100
- 11.10.3 Products 100
- 11.10.4 Strategy 100
- 11.10.5 Key Developments 100
- 11.11 Consern Pharma Private Limited 101
12 Conclusion 102
- 12.1 Key Findings 103
- 12.1.1 CEO’s Viewpoint 103
- 12.1.2 Key Companies to Watch 103
- 12.1.3 Prediction of Dietary Supplements in an Age of Personalized Nutrition Industry 103
13 Appendix 104
- 13.1 Discussion Blue Print 105
- 13.2 Expert Opinion: Oxytocin 107
- 13.3 References 107
Report You Might be Interested
Choose License Type
- USD
- GBP
- EURO
- INR
